Effect of L-Ornithine L-Aspartate on the quality of life in patients with esophageal and gastric variceal bleeding
Annotation. The aim of the study was to evaluate the dynamics of changes in the quality of life of patients with liver cirrhosis complicated by esophageal and gastric variceal bleeding while taking L-Ornithine L-Aspartate. 67 patients with a confirmed diagnosis of liver cirrhosis complicated by esophageal and gastric variceal bleeding were included in the study. All patients were randomly divided into two groups – experimental group (34 patients, standard therapy, supplemented with L-Ornithine L-Aspartate) and comparison group (33 patients, standard therapy). To evaluate the effectiveness of the treatment, the quality of life was assessed using the Gastrointestinal Symptom Rating Scale questionnaire on days 1st–2nd, 7th and 30th. Parametric values were evaluated using Student's t-test, non-parametric values - using the Mann-Whitney test. The intensity of the studied syndromes at the beginning of the study did not differ significantly in both groups. It is explained by the homogeneity of the patient population. In patients of the experimental group, there was a tendency to a more rapid progressive decrease in the intensity of the studied parameters both during their stay in the hospital and after discharge. The improvement in the quality of life after discharge of patients of the experimental group from the hospital is associated with the continuation of the course of taking L-Ornithine L-Aspartate in the form of granules. A moderate decrease in the intensity of the studied syndromes during hospitalization in patients of the comparison group can be explained by the appointment of only standard intensive care. After the patients of the comparison group were discharged from the hospital and the intensive care was stopped, no changes in the quality of life were observed. Thus, the administration of L-Ornithine L-Aspartate to patients with liver cirrhosis complicated by esophageal and gastric variceal bleeding can significantly improve the quality of life and reduce the intensity of dyspeptic, pain, diarrheal, constipation and reflux syndromes. It is planned to evaluate the long-term results of the use of L-Ornithine L-Aspartate in this patient population.
2. Buechter, M., Kahraman, A., Manka, P., Gerken, G., Jochum, C., Canbay, A., & Dechêne, A. (2016). Spleen and Liver Stiffness Is Positively Correlated with the Risk of Esophageal Variceal Bleeding. Digestion, 94 (3), 138–144. doi: 10.1159/000450704.
3. Butterworth, R. F., McPhail, M. J. W. (2019). L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses. Drugs, 79 (1), 31–37. doi: 10.1007/s40265-018-1024-1.
4. Canbay, A., & Sowa, J. P. (2019). L-Ornithine L-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease. Drugs, 79 (1), 39–44. doi: 10.1007/s40265-018-1020-5.
5. Goh, E. T., Stokes, C. S., Sidhu, S. S., Vilstrup, H., Gluud, L. L., & Morgan, M. Y. (2018). L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst. Rev., 5 (5), CD012410. doi: 10.1002/14651858.CD012410.pub2.
6. Gross, M. (2015). Liver cirrhosis and the most common complications: diagnosis and treatment. MMW Fortschr Med., 157 (1), 75–9. doi: 10.1007/s15006-015-2550-3.
7. Hernández-Gea, V., Berbel, C., Baiges, A., & García-Pagán, J. C. (2018). Acute variceal bleeding: risk stratification and management (including TIPS). Hepatol. Int., 12 (1), 81–90. doi: 10.1007/s12072-017-9804-3.
8. Moctezuma Velázquez, C., & Abraldes, J. G. (2017). Non-invasive diagnosis of esophageal varices after Baveno VI. Turk J. Gastroenterol., 28 (3), 159–165. doi: 10.5152/tjg.2017.16744.
9. Tayyem, O., Bilal, M., Samuel, R., Merwat, S. K. (2018). Evaluation and management of variceal bleeding. Dis. Mon., 64 (7), 312–320. doi: 10.1016/j.disamonth.2018.02.001.
10. Zhou, W. C., Zhang, Q. B., & Qiao, L. (2014). Pathogenesis of liver cirrhosis. World J. Gastroenterol., 20 (23), 7312–24. doi: 10.3748/wjg.v20.i23.7312.
This work is licensed under a Creative Commons Attribution 4.0 International License.